Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results

Sutro Biopharma (NASDAQ:STRO) posted its quarterly earnings data on Monday. The company reported ($5.39) EPS for the quarter, missing analysts’ consensus estimates of ($4.66) by ($0.73), FiscalAI reports. Sutro Biopharma had a negative net margin of 206.77% and a negative return on equity of 852.70%. The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $9.26 million.

Sutro Biopharma Stock Performance

STRO stock traded up $0.65 during midday trading on Monday, hitting $21.33. 301,212 shares of the company’s stock were exchanged, compared to its average volume of 150,371. Sutro Biopharma has a one year low of $5.23 and a one year high of $26.54. The stock’s fifty day moving average price is $17.93 and its 200-day moving average price is $12.51. The company has a market cap of $181.52 million, a PE ratio of -0.82 and a beta of 1.47.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sutro Biopharma in a research note on Monday, December 22nd. Wedbush restated a “neutral” rating and issued a $100.00 price objective (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Citizens Jmp upgraded shares of Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 target price for the company in a research note on Tuesday, January 20th. Finally, HC Wainwright boosted their target price on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $31.83.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently made changes to their positions in STRO. Bridgeway Capital Management LLC increased its holdings in shares of Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after acquiring an additional 30,000 shares during the last quarter. Invesco Ltd. boosted its position in Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after purchasing an additional 53,390 shares during the period. Cerity Partners LLC increased its holdings in shares of Sutro Biopharma by 169.9% in the second quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after purchasing an additional 66,372 shares during the last quarter. Qube Research & Technologies Ltd acquired a new position in shares of Sutro Biopharma in the second quarter valued at $82,000. Finally, State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma in the fourth quarter valued at about $86,000. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.